The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Description
Keywords
Humans, Breast Neoplasms, BRCA1 Protein, Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, Chemotherapy, Adjuvant, Neoadjuvant Therapy, Cluster Analysis, Sensitivity and Specificity, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Female, Gene Regulatory Networks, Triple Negative Breast Neoplasms, Biomarkers, Tumor, Poly(ADP-ribose) Polymerase Inhibitors
Journal Title
Breast cancer research : BCR
Conference Name
Journal ISSN
1465-5411
1465-542X
1465-542X
Volume Title
19
Publisher
Publisher DOI
Rights and licensing
Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Department of Health (via National Institute for Health Research (NIHR)) (unknown)
European Commission FP7 Network of Excellence (NoE) (260791)
European Commission FP7 Collaborative projects (CP) (258967)
Department of Health (via National Institute for Health Research (NIHR)) (NF-SI-0515-10090)
EC FP7 CP (258967)
European Commission FP7 Network of Excellence (NoE) (260791)
European Commission FP7 Collaborative projects (CP) (258967)
Department of Health (via National Institute for Health Research (NIHR)) (NF-SI-0515-10090)
EC FP7 CP (258967)